SAN DIEGO, March 28, 2011 /PRNewswire/ -- Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) announced that data highlighting the burden of Clostridium difficile infection using National health insurance claims and survey databases will be presented on April 2, 2011 at the 21st Annual Scientific Meeting of The Society for Healthcare Epidemiology of America (SHEA).
(Logo: http://photos.prnewswire.com/prnh/20090413/LA97352LOGO)Poster Presentation Information:Title:
Rates of Recurrence and Mortality among Patients with a Diagnosis of Clostridium Difficile Infection in the United States: An Analysis Using National Health Insurance Claims and Survey DatabasesPresenter:
Erik R. Dubberke, MD, MSPH, Washington University School of Medicine, St. Louis, MODate:
Saturday, April 2, 2011 Time:
1:00 p.m. to 2:15 p.m. Central TimeLocation:
Hilton Anatole Hotel, Trinity Ballroom, Dallas, TexasPresentation #:
152About OptimerOptimer Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing innovative hospital specialty products that have a positive impact on society. Optimer has two anti-infective product candidates in development, fidaxomicin and Pruvel™ (prulifloxacin). Fidaxomicin is a narrow spectrum antibiotic being developed for the treatment of Clostridium difficile infection (CDI). The FDA granted the Company's request for six-month Priority Review of fidaxomicin, and has assigned a Prescription Drug User Fee Act (PDUFA) goal date of May 30, 2011. The Company also filed a MAA with the European Medicines Agency (EMA) for fidaxomicin. Pruvel™ is a prodrug in the fluoroquinolone class of antibiotics being developed as a treatment for infectious diarrhea. Additional information can be found at http://www.optimerpharma.com.
ContactsOptimer Pharmaceuticals, Inc.
Christina Donaghy, Corporate Communications Manager
John D. Prunty, Chief Financial Officer & VP Finance
Canale Communications, Inc.
Jason I. Spark, Senior Vice President
|SOURCE Optimer Pharmaceuticals, Inc.|
Copyright©2010 PR Newswire.
All rights reserved